Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BPMC NASDAQ:HCM NASDAQ:PTCT NASDAQ:RARE NASDAQ:ZLAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPMCBlueprint Medicines$129.46$128.90$84.25▼$129.65$8.36B0.893.86 million shsN/AHCMHUTCHMED$10.96+2.6%$13.11$10.40▼$19.50$1.86B0.2661,997 shs31,365 shsPTCTPTC Therapeutics$75.14+0.6%$70.54$43.17▼$87.50$6.20B0.561.09 million shs1.07 million shsRAREUltragenyx Pharmaceutical$24.35+1.5%$23.99$18.29▼$42.37$2.36B0.371.49 million shs1.85 million shsZLABZai Lab$17.07-3.2%$20.00$15.96▼$42.00$2.00B0.78912,454 shs1.31 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPMCBlueprint Medicines0.00%0.00%0.00%0.00%+1.18%HCMHUTCHMED+2.38%+0.83%-13.50%-21.60%-36.09%PTCTPTC Therapeutics+0.58%+5.88%+2.29%+16.51%+47.86%RAREUltragenyx Pharmaceutical+1.54%+11.14%-7.97%+14.10%-35.08%ZLABZai Lab-3.23%+2.71%-16.61%-7.08%-58.77%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPMCBlueprint Medicines$129.46$128.90$84.25▼$129.65$8.36B0.893.86 million shsN/AHCMHUTCHMED$10.96+2.6%$13.11$10.40▼$19.50$1.86B0.2661,997 shs31,365 shsPTCTPTC Therapeutics$75.14+0.6%$70.54$43.17▼$87.50$6.20B0.561.09 million shs1.07 million shsRAREUltragenyx Pharmaceutical$24.35+1.5%$23.99$18.29▼$42.37$2.36B0.371.49 million shs1.85 million shsZLABZai Lab$17.07-3.2%$20.00$15.96▼$42.00$2.00B0.78912,454 shs1.31 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPMCBlueprint Medicines0.00%0.00%0.00%0.00%+1.18%HCMHUTCHMED+2.38%+0.83%-13.50%-21.60%-36.09%PTCTPTC Therapeutics+0.58%+5.88%+2.29%+16.51%+47.86%RAREUltragenyx Pharmaceutical+1.54%+11.14%-7.97%+14.10%-35.08%ZLABZai Lab-3.23%+2.71%-16.61%-7.08%-58.77%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPMCBlueprint Medicines 2.00Hold$129.00-0.36% DownsideHCMHUTCHMED 2.40Hold$16.8053.28% UpsidePTCTPTC Therapeutics 2.71Moderate Buy$91.3621.58% UpsideRAREUltragenyx Pharmaceutical 2.82Moderate Buy$59.56144.61% UpsideZLABZai Lab 2.63Moderate Buy$45.83168.50% UpsideCurrent Analyst Ratings BreakdownLatest BPMC, ZLAB, HCM, RARE, and PTCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2026PTCTPTC Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$75.00 ➝ $108.006/4/2026ZLABZai Lab Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/28/2026HCMHUTCHMED Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$13.605/27/2026PTCTPTC Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$76.00 ➝ $85.005/22/2026ZLABZai Lab Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/21/2026RAREUltragenyx Pharmaceutical Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$84.00 ➝ $96.005/11/2026PTCTPTC Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)5/11/2026ZLABZai Lab Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/8/2026RAREUltragenyx Pharmaceutical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/8/2026PTCTPTC Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$94.005/8/2026PTCTPTC Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$75.00 ➝ $90.00(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPMCBlueprint Medicines$562.12M14.87N/AN/A$4.70 per share27.54HCMHUTCHMED$548.51M3.49$2.77 per share3.96$7.17 per share1.53PTCTPTC Therapeutics$1.73B3.60$8.83 per share8.51($2.56) per share-29.35RAREUltragenyx Pharmaceutical$673M3.56N/AN/A($0.83) per share-29.34ZLABZai Lab$460.16M4.21N/AN/A$6.39 per share2.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPMCBlueprint Medicines-$67.09M-$2.47N/A199.17N/A-27.70%-64.60%-17.22%N/AHCMHUTCHMED$456.91MN/AN/A22.37N/AN/AN/AN/A8/3/2026 (Estimated)PTCTPTC Therapeutics$682.64M-$2.33N/A35.613.44-22.58%-362.45%-6.76%8/6/2026 (Estimated)RAREUltragenyx Pharmaceutical-$575M-$6.11N/AN/AN/A-91.03%-1,024.42%-45.78%8/4/2026 (Estimated)ZLABZai Lab-$175.54M-$1.62N/AN/AN/A-39.29%-24.32%-15.52%8/6/2026 (Estimated)Latest BPMC, ZLAB, HCM, RARE, and PTCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026PTCTPTC Therapeutics-$0.45-$0.03+$0.42-$0.03$217.42 million$272.55 million5/7/2026Q1 2026ZLABZai Lab-$0.5262-$0.46+$0.0662-$0.50$108.43 million$99.61 million5/5/2026Q1 2026RAREUltragenyx Pharmaceutical-$1.4878-$1.84-$0.3522-$1.84$158.19 million$136.00 million4/1/2026Q1 2026ZLABZai LabN/A-$0.50N/A-$0.50N/A$99.61 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBPMCBlueprint MedicinesN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/AZLABZai LabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPMCBlueprint Medicines1.012.802.75HCMHUTCHMED0.054.964.83PTCTPTC TherapeuticsN/A2.442.36RAREUltragenyx PharmaceuticalN/A2.021.85ZLABZai LabN/A2.402.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPMCBlueprint MedicinesN/AHCMHUTCHMED8.82%PTCTPTC TherapeuticsN/ARAREUltragenyx Pharmaceutical97.67%ZLABZai Lab41.65%Insider OwnershipCompanyInsider OwnershipBPMCBlueprint Medicines4.21%HCMHUTCHMED3.60%PTCTPTC Therapeutics5.50%RAREUltragenyx Pharmaceutical5.20%ZLABZai Lab4.88%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBPMCBlueprint Medicines64064.58 million61.86 millionOptionableHCMHUTCHMED1,796174.47 million168.19 millionNot OptionablePTCTPTC Therapeutics1,41082.95 million78.39 millionOptionableRAREUltragenyx Pharmaceutical1,37198.49 million93.37 millionOptionableZLABZai Lab1,784113.41 million107.88 millionOptionableBPMC, ZLAB, HCM, RARE, and PTCT HeadlinesRecent News About These CompaniesPfizer, Zai Lab win China nod for cervical cancer therapy TivdakJune 9, 2026 | msn.comZai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical CancerJune 8, 2026 | businesswire.comZai Lab (ZLAB) Is Down 6.0% After Leadership Shake-Up And 2026 Data Focus Has The Bull Case Changed?June 6, 2026 | finance.yahoo.comZai Lab (ZLAB) Announces Senior Leadership ChangesJune 6, 2026 | finance.yahoo.com5 Stocks That Have the Potential to Rise 1000%June 5, 2026 | insidermonkey.comZai Lab (ZLAB) Q1 2026 Earnings TranscriptJune 2, 2026 | fool.comZai Lab announces departure of president and COO Josh SmileyMay 22, 2026 | msn.comZai Lab announces departure of president and COO Josh SmileyMay 22, 2026 | msn.comZai Lab Announces Changes to Senior Leadership TeamMay 21, 2026 | businesswire.comZai Lab (NASDAQ:ZLAB) CEO Ying Du Sells 50,000 SharesMay 16, 2026 | insidertrades.comZai Lab: A Speculative Bet On Global Oncology, With A Greater China Bag AttachedMay 14, 2026 | seekingalpha.comZai Lab Limited 2026 Q1 - Results - Earnings Call PresentationMay 11, 2026 | seekingalpha.comZai Lab Limited (NASDAQ:ZLAB) Analysts Are Cutting Their Estimates: Here's What You Need To KnowMay 11, 2026 | finance.yahoo.comZai Lab wins FDA fast track status for cancer drug Zocilurtatug PelitecanMay 11, 2026 | msn.comZai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)May 11, 2026 | businesswire.comZai Lab Limited (ZLAB) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comZai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to SayMay 7, 2026 | zacks.comZai Lab Announces First Quarter 2026 Financial Results and Recent Corporate UpdatesMay 7, 2026 | finance.yahoo.comAssessing Zai Lab (ZLAB) Valuation After Recent Share Price Momentum And Analyst Target ResetApril 29, 2026 | finance.yahoo.comZai Lab Limited (ZLAB) Discusses Intracranial Activity of a New Therapy in Small Cell Lung Cancer With Brain Metastases - SlideshowApril 22, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 20263 Rare Earth Stocks That Win No Matter What China Does NextBy Bridget Bennett | May 24, 2026Mirum Pharma: A Rare Disease Growth Story to WatchBy Chris Markoch | May 20, 2026USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal LoomsBy Leo Miller | May 20, 2026BPMC, ZLAB, HCM, RARE, and PTCT Company DescriptionsBlueprint Medicines NASDAQ:BPMCBlueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.HUTCHMED NASDAQ:HCM$10.96 +0.28 (+2.62%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$10.96 0.00 (0.00%) As of 06/12/2026 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.PTC Therapeutics NASDAQ:PTCT$75.14 +0.43 (+0.58%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$75.14 0.00 (0.00%) As of 06/12/2026 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Ultragenyx Pharmaceutical NASDAQ:RARE$24.35 +0.37 (+1.54%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$24.02 -0.34 (-1.38%) As of 06/12/2026 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.Zai Lab NASDAQ:ZLAB$17.07 -0.57 (-3.23%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$17.08 +0.01 (+0.06%) As of 06/12/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
